Table 1.
Characteristics of included studies gemcitabine and nab-paclitaxel (GEM-NAB) vs. 5-fluorouracil, oxaliplatin, and irinotecan (FOLFIRINOX).
| Author/Year | N° pts | Country | Type of Study | Follow up (Months) | PS 0–1% GN/F | Median Age GN/F (Years) | Stage (LAD/Metastatic) GN vs. F | Abnormal Bilirubin % GN vs. F | Liver Metastases % GN vs. F | Location(Head) GN vs. F | CA 19.9 (Median) GN vs. F | Biliary Stent % GN vs. F |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Braiteh 2017 [9] | 202 | USA | Retrospective | - | 82 vs. 82 | 69/61.5 | 0/88 vs. 0/89 | - | 64 vs. 73 | - | 48 vs. 37 | - |
| Dhir 2018 [10] | 193 | USA | Retrospective | 27.5 | - | 69/63 | 59.2 vs. 79.4/0 vs. 0 | - | - | - | 235 vs 243 | - |
| Cartwright 2018 [6] | 314 | USA | Retrospective | - | 76.8/90.5 | 68/61 | 0/100 vs. 0/100 | - | 33.1 vs. 33.5 | - | - | - |
| Kang 2018 [8] | 308 | Korea | Retrospective | 19.6 | 96.6/99. 4 | 62/60 | 0/100 vs. 0/100 | - | 61.1 vs. 67.9 | 32.2 vs. 39.7 | 443 vs. 576 | - |
| Hegewisch-Becker 2018 [11] | 773 | Germany | Retrospective | - | 89.6 vs. 95.8 | 71/60 | -/89 vs. 90 | 9.8 vs. 7.4 | - | 52.4 vs. 52.5 | - | - |
| Kim 2018 [12] | 654 | USA | Retrospective | 9 | 70.3 vs. 91.5 | 64.59/59.03 | 0/100 vs. 100 | - | 75.34 vs. 75.73 | 50.5 vs. 51.3 | - | - |
| Muranaka 2017 [13] | 38 | Japan | Retrospective | 11.9–8.3 (F-GN) | 100 vs. 100 | 66.5/63 | 13.6 vs. 43.8/86.4 vs. 56.2 | - | - | - | 305.6 vs. 128.7 | 9.1 vs. 18.8 |
| Peixoto 2015 [7] | 331 | Canada | Retrospective | - | - | - | - | - | - | - | - | - |
| Tahara 2018 [14] | 27 | Japan | Retrospective | - | 100/100 | 63 vs. 62 | - | 0 vs. 0 | 26.6 vs. 16.6 | 66.6 vs. 50 | - | - |
| Terashima 2018 [15] | 67 | Japan | Retrospective | 5.6 | - vs. 85.1 | - | - | - | - | - | - | - |
| Wang 2017 [16] | 179 | Canada | Retrospective | 8.5 | 59/93 | 68/60 | -/75.9 vs. 59.8 | 10 vs. 10 | 34.8 vs. 30.1 | 48.3 vs. 67.4 | 1228 vs. 415 | 20.7 vs. 32.6 |
| Caponnetto 2017 [17] | 43 | Italy | Retrospective | - | 100/100 | - | 0/100 vs. 0/100 | - | - | - | - | - |
| Cho 2018 [18] | 167 | Korea | Cohort study | 7.9 | - | 65/54 | 0/100 vs. 0/100 | - | - | - | - | - |
| Kasi 2017 [19] | 154 | US | Retrospective | - | 83/90 | 63/61 | 30/70 vs. 48/52 | - | - | 55 vs. 63 | - | 20/41 |
| Schmidt 2016 [3] | 56 | US | Retrospective | - | - | - | 100/100 | - | - | - | - | - |
| Yamamoto 2017 [20] | 207 | Japan | Retrospective | - | - | - | - | - | - | - | - | - |
GN: Gemcitabine—Nab-paclitaxel; F: FOLFIRINOX; LAD: locally advanced disease; N°: number; pts: patients; PS: performance status